When will caplyta go generic?

When can we expect Caplyta to go off-patent?

Caplyta, the brand name for lumateperone, is an atypical antipsychotic medication developed by Intra-Cellular Therapies, Inc. for the treatment of schizophrenia and bipolar depression. As of now, [1] the drug's patent protection is in effect, which may delay the entry of generic alternatives into the market.

What is the current patent status?

Lumateperone's patent was granted in 2019 [2] and is scheduled to expire in 2035, which is 17 years from the date of filing [3]. However, patent terms can be influenced by regulatory factors, such as FDA approvals and patent extensions.

How soon can we expect generic Caplyta?

While the patent expiration in 2035 is a rough estimate, it's also possible that patent litigation or settlements could accelerate the availability of generic alternatives. However, according to DrugPatentWatch.com [4], Intra-Cellular Therapies has filed for and received multiple patent extensions for Caplyta.

What are the potential consequences of a delayed generic entry?

The market exclusivity for Caplyta may last longer than expected, maintaining high prices and limiting competition. This can have significant implications for patients, healthcare providers, and the pharmaceutical industry as a whole.

References

[1] Intra-Cellular Therapies, Inc. (2023). Caplyta (Lumateperone). https://www.intracellular.com/product/caplyta

[2] United States Patent and Trademark Office. (2019). Patent 10, 434, 115 B2.

[3] DrugPatentWatch.com. (2023). Patent and Exclusivity Details for CAPLYTA (Lumateperone).

[4] DrugPatentWatch.com. (2023). Patent and Exclusivity Details for CAPLYTA (Lumateperone).

Sources

1. DrugPatentWatch.com
2. Intra-Cellular Therapies, Inc.
3. United States Patent and Trademark Office